Beam president awarded 40,000 RSUs

Ciaramella Giuseppe reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 04/02/2026 - 05:15 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Ciaramella Giuseppe reported acquisition or exercise transactions in this Form 4 filing.

Beam Therapeutics Inc. reported that President Giuseppe Ciaramella received an equity grant of 40,000 restricted stock units (RSUs) of common stock. Each RSU represents the right to receive one Beam share and will vest in four substantially equal annual installments, subject to his continued service. Following this award, he directly holds 230,216 shares of Beam common stock, including the RSUs.

Insider Trade Summary

Grant/Award: 40,000 shares

Grant/Award 1 txn

Insider Ciaramella Giuseppe

Role President

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	40,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 230,216 shares (Direct)

Holdings Before and After: Common Stock, 190,216 to 230,216 shares (Direct)

Footnotes (1)

1. F1. Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

Key Figures

RSUs granted: 40,000 units Shares following transaction: 230,216 shares Grant price: $0.0000 per share +1 more

4 metrics

RSUs granted 40,000 units Restricted stock units granted on March 31, 2026

Shares following transaction 230,216 shares Total direct Beam common stock holdings after grant

Grant price $0.0000 per share Reported transaction price for RSU grant

Vesting schedule 4 annual installments RSUs vest over four substantially equal anniversaries

Key Terms

restricted stock units ("RSUs"), 2019 Equity Incentive Plan, vesting

3 terms

restricted stock units ("RSUs") financial

"Represents restricted stock units ("RSUs") granted to the Reporting Person"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

2019 Equity Incentive Plan financial

"granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan"

vesting financial

"The RSUs vest in four substantially equal installments on each of the first four anniversaries"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Beam Therapeutics (BEAM) president Giuseppe Ciaramella receive in this Form 4?

Beam Therapeutics’ president Giuseppe Ciaramella received a grant of 40,000 restricted stock units (RSUs). Each RSU represents the contingent right to one share of Beam common stock under the company’s 2019 Equity Incentive Plan, as reported in the Form 4.

How do the 40,000 RSUs granted to BEAM’s president vest over time?

The 40,000 RSUs vest in four substantially equal installments on each of the first four anniversaries of the grant date. Vesting is conditioned on Giuseppe Ciaramella’s continued service with Beam Therapeutics through each applicable vesting date.

What does each RSU granted to Beam Therapeutics’ president represent?

Each RSU granted to Beam Therapeutics’ president represents the contingent right to receive one share of Beam’s common stock. Delivery of the shares occurs as the RSUs vest according to the four-year vesting schedule described in the Form 4 footnote.

Under which plan were the 40,000 RSUs to BEAM’s president granted?

The 40,000 RSUs were granted under the Beam Therapeutics Inc. 2019 Equity Incentive Plan. This plan provides equity-based awards such as restricted stock units to eligible participants as part of their compensation and alignment with shareholder interests.

How many Beam Therapeutics shares does the president hold after this RSU grant?

After the RSU grant, President Giuseppe Ciaramella directly holds 230,216 shares of Beam Therapeutics common stock. This figure includes the 40,000 RSUs reported in the Form 4, reflecting his updated equity position following the award.

Is the RSU award to BEAM’s president a market purchase of shares?

No, the RSU award is a grant, not a market purchase. The Form 4 shows transaction code "A" for a grant or award acquisition, with a per-share price of 0.0000, indicating compensation rather than an open-market buy transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ciaramella Giuseppe

(Last) (First) (Middle)

C/O BEAM THERAPEUTICS INC.,

238 MAIN STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/31/2026		A		40,000(1)	A	$0	230,216	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

	By: /s/ Christine Bellon, Attorney-in-fact	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)